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Abstract
Accurate prediction of clinical changes of mild cognitive impairment (MCI) patients, including both qualitative change (i.e.,
conversion to Alzheimer’s disease (AD)) and quantitative change (i.e., cognitive scores) at future time points, is important for
early diagnosis of AD and for monitoring the disease progression. In this paper, we propose to predict future clinical
changes of MCI patients by using both baseline and longitudinal multimodality data. To do this, we first develop a
longitudinal feature selection method to jointly select brain regions across multiple time points for each modality.
Specifically, for each time point, we train a sparse linear regression model by using the imaging data and the corresponding
clinical scores, with an extra ‘group regularization’ to group the weights corresponding to the same brain region across
multiple time points together and to allow for selection of brain regions based on the strength of multiple time points
jointly. Then, to further reflect the longitudinal changes on the selected brain regions, we extract a set of longitudinal
features from the original baseline and longitudinal data. Finally, we combine all features on the selected brain regions,
from different modalities, for prediction by using our previously proposed multi-kernel SVM. We validate our method on 88
ADNI MCI subjects, with both MRI and FDG-PET data and the corresponding clinical scores (i.e., MMSE and ADAS-Cog) at 5
different time points. We first predict the clinical scores (MMSE and ADAS-Cog) at 24-month by using the multimodality data
at previous time points, and then predict the conversion of MCI to AD by using the multimodality data at time points which
are at least 6-month ahead of the conversion. The results on both sets of experiments show that our proposed method can
achieve better performance in predicting future clinical changes of MCI patients than the conventional methods.
Citation: Zhang D, Shen D, ADNI (2012) Predicting Future Clinical Changes of MCI Patients Using Longitudinal and Multimodal Biomarkers. PLoS ONE 7(3):
e33182. doi:10.1371/journal.pone.0033182
Editor: Kewei Chen, Banner Alzheimer’s Institute, United States of America
Received January 4, 2012; Accepted February 5, 2012; Published March 22, 2012
Copyright:  2012 Zhang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported in part by NIH grants EB006733, EB008374, EB009634, and MH088520, by the National Science Foundation of China under
grants No. 60875030 and No. 61075010, and also by the National Basic Research Program of China (973 Program) grant No. 2010CB732505. The funders had no
role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: dgshen@med.unc.edu
Introduction
Alzheimer’s disease (AD), the most common form of dementia,
is a progressive age-related neurodegenerative disease usually
diagnosed in people over 65 years of age. It is reported that there
are 26.6 million AD sufferers worldwide, and 1 in 85 people will
be affected by 2050 [1]. Mild cognitive impairment (MCI) is a
prodromal stage of AD, and the existing studies have suggested
that the individuals with amnestic MCI tend to progress to
probable AD at a rate of approximately 10% to 15% per year.
Thus, accurate diagnosis of AD, especially MCI, is of great
importance for timely therapy and possible delay of the disease.
Over the past several years, many high-dimensional pattern
classification methods have been developed for classification of AD
and MCI based on different modalities of biomarkers, e.g., the
structural brain atrophy measured by magnetic resonance imaging
(MRI) [2,3,4], the metabolic brain alterations measured by
fluorodeoxyglucose positron emission tomography (FDG-PET)
[5,6], and the pathological amyloid depositions measured through
cerebrospinal fluid (CSF) [3,7,8,9], etc.
Recently, due to the importance of MCI in early diagnosis of
AD, there is a growing interest in predicting future clinical changes
of MCI subjects from brain imaging data [10,11,12,13,14].
Generally, there are two kinds of clinical changes for MCI
subjects at future time points. First, some MCI subjects will
convert into AD after some time (i.e., MCI converters, MCI-C for
short), while others will never convert (i.e., MCI non-converters,
MCI-NC for short). It’s important to predict whether a certain
MCI subject will convert into AD at future time points or not. This
is a qualitative prediction, which can be solved through
classification between MCI-C and MCI-NC. Second, because
AD is a progressive neurodegenerative disease, there exist
continuous changes between the measured clinical scores, e.g.,
Mini Mental State Examination (MMSE) and Alzheimer’s Disease
Assessment Scale - Cognitive Subscale (ADAS-Cog), at follow-up
time points. Thus, it’s important to predict the future clinical
scores based on the data at previous time points, which is
especially helpful for monitoring disease progression. However,
different from predicting MCI conversion, predicting future
clinical scores requires a quantitative prediction, which needs to
be solved by learning a regression model, instead of a classification
model.
A number of high-dimensional classification and regression
methods have been used for predicting future clinical changes of
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[10,11,15,16] and the future clinical cognitive scores
[13,14,17,18]. However, most existing methods perform the
prediction using only the baseline data, although in practice there
may also exist longitudinal data at the follow-up time points which
often contains useful longitudinal information for prediction. It’s
worth noting that, in the group-based analysis methods,
longitudinal data have been already used for measuring longitu-
dinal changes of brain through regions of interest (ROI) or voxel-
based method for decades [19,20], but it’s until very recently that
only a few researchers started to use longitudinal data for
individual-based classification, i.e., identifying MCI-C from
MCI-NC [12,21,22,23]. On the other hand, to the best of our
knowledge, none of the existing regression methods ever exploited
the longitudinal data for predicting future clinical scores of MCI
subjects.
In this paper, we propose to predict the MCI-to-AD conversion
and the future clinical scores of MCI patients by using both
baseline and longitudinal multimodality data. Specifically, we first
develop a longitudinal feature selection method which can jointly
select the brain regions across multiple time points for each
modality. Also, in the longitudinal feature selection method, for
each time point we train a sparse linear regression model using the
imaging data and corresponding clinical scores, with an extra
‘group regularization’ to group the weights corresponding to the
same brain region across multiple time points together and to
allow for selection of brain regions based on the strength of
multiple time points jointly. After selecting the brain regions using
the longitudinal feature selection, we then extract a set of
longitudinal features from the original baseline and longitudinal
data to further reflect the longitudinal changes on those selected
brain regions. Finally, we combine all features on the selected
brain regions from different modalities for prediction, by using our
previously proposed multi-kernel support vector machines (SVM)
[24,25].
To evaluate our method, we perform two sets of experiments
on 88 MCI subjects, including 38 MCI converters (MCI-C) and
50 MCI non-converters (MCI-NC), from the ADNI database.
Here, each subject has both MRI and FDG-PET data and the
corresponding clinical scores, including MMSE and ADAS-Cog,
at 5 different time points (i.e., baseline, 6-month, 12-month, 18-
montha and 24-month). In our first set of experiments, we
predict the clinical scores (including MMSE and ADAS-Cog) at
24-month by using the multimodality data at previous time
points (i.e., baseline, 6-month, 12-month and 18-month). In our
second set of experiments, we predict the conversion of MCI by
using the multimodality data at time points which are at least 6-
month ahead of the conversion. Our hypothesis is that the
proposed pattern analysis method based on both baseline and
longitudinal multimodality data would perform better in
predicting the future changes of MCI patients than the
conventional methods.
Methods
The data used in the preparation of this paper were obtained
from the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
database (www.loni.ucla.edu/ADNI). The ADNI was launched in
2003 by the National Institute on Aging (NIA), the National
Institute of Biomedical Imaging and Bioengineering (NIBIB), the
Food and Drug Administration (FDA), private pharmaceutical
companies, and non-profit organizations, as a $60 million, 5-year
public-private partnership. The primary goal of ADNI has been to
test whether the serial MRI, PET, other biological markers, and
clinical and neuropsychological assessment can be combined to
measure the progression of MCI and early AD. Determination of
sensitive and specific markers of very early AD progression is
intended to aid researchers and clinicians to develop new
treatments and monitor their effectiveness, as well as lessen the
time and cost of clinical trials.
The Principal Investigator of this initiative is Michael W.
Weiner, MD, VA Medical Center and University of California –
San Francisco. ADNI is the result of efforts of many coinvestiga-
tors from a broad range of academic institutions and private
corporations, and subjects have been recruited from over 50 sites
across the U.S. and Canada. The initial goal of ADNI was to
recruit 800 adults, ages 55 to 90, to participate in the research,
approximately 200 cognitively normal older individuals to be
followed for 3 years, 400 people with MCI to be followed for 3
years and 200 people with early AD to be followed for 2 years. For
up-to-date information, see www.adni-info.org.
Ethics statement
Study subjects gave written informed consent at the time of
enrollment for imaging and genetic sample collection and
completed questionnaires approved by each participating sites
Institutional Review Board (IRB). The authors state that they have
obtained approval from the ADNI Data Sharing and Publications
Committee for use of the data and confirm that the data was
analyzed anonymously.
Subjects
The ADNI general eligibility criteria are described at www.
adni-info.org. Briefly, subjects are between 55–90 years of age,
having a study partner able to provide an independent evaluation
of functioning. Specific psychoactive medications will be excluded.
General inclusion/exclusion criteria are as follows: 1) healthy
subjects: MMSE scores between 24–30, a Clinical Dementia
Rating (CDR) of 0, non-depressed, non MCI, and nondemented;
2) MCI subjects: MMSE scores between 24–30, a memory
complaint, having objective memory loss measured by education
adjusted scores on Wechsler Memory Scale Logical Memory II, a
CDR of 0.5, absence of significant levels of impairment in other
cognitive domains, essentially preserved activities of daily living,
and an absence of dementia; and 3) Mild AD: MMSE scores
between 20–26, CDR of 0.5 or 1.0, and meets the National
Institute of Neurological and Communicative Disorders and
Stroke and the Alzheimer’s Disease and Related Disorders
Association (NINCDS/ADRDA) criteria for probable AD. Study
subjects gave written informed consent at the time of enrollment
for imaging and genetic sample collection and completed
questionnaires approved by each participating sites Institutional
Review Board (IRB).
In this paper, 88 MCI subjects with all corresponding MRI and
PET data as well as two cognitive scores (MMSE and ADAS-Cog)
at 5 different time points (baseline, 6-month, 12-month, 18-month
and 24-month) are included. In particular, it contains 35 MCI
converters (MCI-C) and 50 MCI non-converters (MCI-NC).
Table 1 lists the demographics of all these subjects.
MRI and PET
A detailed description on acquiring MRI and PET data from
ADNI as used in this paper can be found at [24,25]. Briefly,
structural MR scans were acquired from 1.5 T scanners. Raw
Digital Imaging and Communications in Medicine (DICOM)
MRI scans were downloaded from the public ADNI site (www.
loni.ucla.edu/ADNI), reviewed for quality, and automatically
corrected for spatial distortion caused by gradient nonlinearity
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minutes post-injection, averaged, spatially aligned, interpolated
to a standard voxel size, intensity normalized, and smoothed to
ac o m m o nr e s o l u t i o no f8m mf u l lw i d t ha th a l fm a x i m u m .
Image analysis
Image pre-processing is performed for all MR and PET images.
First, we perform anterior commissure (AC) - posterior commis-
sure (PC) correction on all images, and use the N3 algorithm [26]
to correct the intensity inhomogeneity. Next, we do skull-stripping
on structural MR images using both brain surface extractor (BSE)
[27] and brain extraction tool (BET) [28], followed by manual
edition and intensity inhomogeneity correction. After removal of
cerebellum, FAST in the FSL package [29] is used to segment
structural MR images into three different tissues: grey matter
(GM), white matter (WM), and cerebrospinal fluid (CSF). Then, a
fully automatic 4-dimensional atlas warping method called 4D
HAMMER [30] is used to register all different time-point images
of each subject to a template with 93 manually labeled ROIs [31].
Here, besides HAMMER, other registration methods [32,33,34,
35,36] can also be used. After registration, we can label all images
based on the 93 labeled ROIs in the template. For each of the 93
ROI regions in the labeled MR image, we compute the total tissue
GM, WM and CSF volumes of that region and use them as
features. For PET image, we first align it to its respective MR
image of the same subject at the same time point by using a rigid
registration, and then compute the average intensity of each ROI
in the PET image as a feature.
Overview of the proposed method
Fig. 1 gives the flowchart of the proposed method, which gives
an overview of the major steps employed to use multimodality
longitudinal data for prediction. In this study, we use two imaging
modalities, i.e., MRI and PET. Thus, for each subject, we have
both MRI and PET images, as well as the two cognitive scores
(MMSE and ADAS-Cog), at different time points. For each MRI
or PET image of each subject at each time point, image pre-
processing steps (including registration and labeling) as intro-
duced in Image analysis subsection is first performed to obtain the
regional MRI and PET features, respectively. After obtaining the
regional MRI and PET features, longitudinal feature selection is
first performed to select the common brain regions across
multiple time points for MRI and PET, respectively. Then, we
extract a set of longitudinal features from the original baseline
and longitudinal data to characterize the longitudinal changes on
the selected brain regions for MRI and PET, respectively. Besides
features from MRI and PET, we also use the two cognitive scores
(MMSE and ADAS-Cog) as features and put those scores at
different time points into a feature vector. Finally, we combine
both imaging and cognitive features for prediction by using our
previously proposed multi-kernel SVM. In what follows, we will
detail the three major steps in our methods, i.e., 1) longitudinal
feature selection, 2) longitudinal feature extraction, and 3) multi-
kernel SVM.
Longitudinal feature selection
Since not all brain regions are related to AD, those irrelevant
features derived from the unrelated brain regions are better
removed by feature selection before performing classification and
regression. However, to our knowledge, most existing feature
selection methods are designed for the single-time-point image,
i.e., each subject has only the single-time-point data with the
corresponding targets. This feature selection method cannot be
easily extended for feature selection on multiple time-point images
(i.e., baseline plus longitudinal data). To distinguish from the
existing feature selection methods based on the single-time-point
data, we call our feature selection on multiple time-point (baseline
plus longitudinal) data as longitudinal feature selection method, as
formulated below. It’s worth noting that, in this study, we focus on
the linear feature selection based on feature weight learning as
detailed next.
Assume that we have N training subjects s1,:::,si,:::,sN fg and
each subject si has T imaging data at T different time points,
represented as xij
   T
j~1, where xij[R1|D is a D-dimensional row
vector. Denote Xj~ x1j,:::,xij,:::,xNj
  
([RN|D) as the training
data matrix at the j-th time point, and yj ([RN) is the
corresponding target outputs at the j-th time point. Longitudinal
feature selection learns a feature weight vector wj ([RD) from Xj
and yj, with a ‘group regularization’ constraint on the corre-
sponding elements of wj across T time points, as formulated in the
following objective function:
min
W
1
2
X T
j~1
yj{Xjwj
       2
2zl
X D
d~1
wd        
2 ð1Þ
where W~ w1,:::,wj,::::,wT
  
([RD|T), and wd is its d-th row
vector. The regularization parameter l balances the relative
contributions of the two terms and also controls the ‘sparsity’ of
the linear models. In fact, the last term in the above objective
function is equivalent to the l2,1-norm of the matrix W, i.e., first
computing l2-norm on each row vector and then computing l1-
norm on column vector with l2c-norms of row vectors. It’s worth
noting that the use of l2-norm on row vectors forces the weights
corresponding to the d-th feature across multiple time points to be
grouped together and the further use of l1-norm tends to select
features based on the strength of T time points jointly. In other
words, features (in brain regions) will be selected as a group across
all time points together. This formulation is important for
tracking the longitudinal changes of brain regions with progres-
sion of disease.
Fig. 2 gives an illustration on the longitudinal feature selection.
Here, at each time point j,w eh a v eb a s e l i n e( f o rt i m ep o i n tj=1)
or longitudinal (for time point j.1) image data Xj(each row
denotes a subject with features gotten from different brain
Table 1. Subject information.
MCI-C (n=38) MCI-NC (n=50)
Female/Male 15/23 14/36
Age 74.767.2 74.367.9
Education 15.962.8 16.062.9
MMSE (baseline) 26.961.7 27.461.6
MMSE (24 months) 23.963.6 27.062.6
(p,0.0001) (p=0.406)
ADAS-Cog (baseline) 12.763.9 9.664.1
ADAS-Cog (24 months) 16.166.2 11.065.9
(p=0.0052) (p=0.1755)
MCI=Mild Cognitive Impairment, MCI-C=MCI converter, MCI-NC=MCI non-
converter, MMSE=Mini-Mental State Examination, ADAS-Cog=Alzheimer’s
Disease Assessment Scale - Cognitive Subscale.
doi:10.1371/journal.pone.0033182.t001
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ADAS-Cog. By imposing a ‘group regularization’ on the
corresponding elements of each feature weight vector wj,
longitudinal feature selection achieves the goal of ‘group
selection’ of features (or brain regions).
It is easy to know that the above objective function in Eq. (1)
reduces to the standard l1-norm regularized optimization
problem in Lasso [37] when only a single (baseline) time point
of data is available, i.e., T=1. Also, because of the use of l2,1-
norm for W in the above objective function, it will result in a
weight matrix W with elements in some rows being all zeros. For
the goal of feature selection, we can just keep those features with
non-zero weights. For implementation, there have been a number
of algorithms available in machine learning and statistics
communities to solve the linear regression problem with l2,1-
norm regularization [38–39]. In this paper, the SLEP toolbox
[40] is used to solve the objective function in our longitudinal
feature selection method.
Longitudinal feature estimation
For each selected brain region obtained from the longitudinal
feature selection step, besides using its corresponding features
from the imaging data at each time point, we can also derive
some new features to reflect the longitudinal changes on
specific brain regions across different time points. For example,
in thickness-based measures, the thinning speed [41], which
can be seen as a first-order feature, is computed by solving the
first-order linear regression on thickness values across all time
points in a specific brain region. In this study, to extract more
higher-order features, we solve the following higher-order
linear equation for each subject and for each selected brain
region:
u~cTtT{1z:::zcktk{1z:::zc2tzc1 ð2Þ
where t (=1,…,T) denotes different time point, u is the
corresponding imaging feature, and c1,c2,:::,ck,:::,cT are the
coefficients. It’s easy to derive the solution for the coefficients by
substituting each t (for=1,…,T) and the correspondinguinto the
above equation. Specifically, denoting xd
ij as the selected imaging
feature d for subject siat the j-th time point, by respectively
substituting=1,…,Tand u~xd
ij (j=1,…,T) into the above equa-
tion, we can obtain the corresponding coefficients, denoted as cd
ij
(=1,…,T), which are regarded as new longitudinal features.
Multi-kernel SVM
Multimodality data can contain complementary information. In
ADNI dataset, many subjects have both MRI and PET imaging
data, CSF biological data, MMSE and ADAS-Cog cognitive data,
etc. It has been shown that the use of multimodal data can achieve
better classification and regression performance than the use of
only the single modality data. In this study, we will use our
previously proposed multi-kernel SVM method, evaluated on both
classification [24] and regression [25] problems, to combine the
features from different modalities.
Assume that each subject si has M different modalities of data at
each of the T different time points, which can be represented as
x
(1)
ij ,:::,x
(m)
ij ,:::,x
(M)
ij
no
, i~1,:::,N;j~1,:::,T. For each modality of
each subject, we perform the above longitudinal feature selection
to select a subset of brain regions and obtain the corresponding
selected features, represented as x’
(1)
ij ,:::,x’
(m)
ij ,:::,x’
(M)
ij
no
,
i~1,:::,N;j~1,:::,T. Similarly, for each modality of each subject,
Figure 1. Flowchart of the proposed method.
doi:10.1371/journal.pone.0033182.g001
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described longitudinal feature extraction method to further extract
the corresponding longitudinal features, denoted as
c
(1)
ij ,:::,c
(m)
ij ,:::,c
(M)
ij
no
, i~1,:::,N;j~1,:::,T. Finally, for ease of
subsequent classification and regression, for each modality of each
subject si, we generate a final feature vector for representation
x’
(1)
i ,:::,x’
(m)
i ,:::,x’
(M)
i
no
, i~1,:::,N, by concatenating its corre-
sponding feature vectors x’
(m)
ij and c
(m)
ij , j~1,:::,T, into a single
vector x’
(m)
i .
The main idea of multi-kernel SVM is to first construct an
individual kernel for each modality of data and then learn a mixed
kernel based on the linear combination of all individual kernels. In
our previous works, multi-kernel SVM has been proposed for both
regression [25] and classification [24] problems. For example, the
objective function of multi-kernel SVM for classification can be
defined below [24]:
max
a,a 
1
2
X N
i~1
ai{
1
2
X N
i,j~1
aiajzizj
X M
m~1
bmk(m) x’
(m)
i ,x’
(m)
j
  
s:t:
X N
i~1
aizi~0
0ƒaiƒC,i~1,:::,N:
ð3Þ
where k(m)(:,:)is the individual kernel function defined for the m-th
modality, and bm§0denotes the combining weight on the m-th
modality with the constraint
P
m bm~1. Also,zi is the corre-
sponding target output of classification for subject si, i.e., the class
label indicating whether subject si will convert into AD at future
time point. A similar objective function of multi-kernel SVM for
regression has been given in [25]. It’s worth nothing that multi-
kernel SVM can be efficiently solved with the conventional
SVM solver, e.g., LIBSVM, by defining a mixed kernel
k(x’i,x’j)~
PM
m~1 bmk(m) x’
(m)
i ,x’
(m)
j
  
as done in [24,25].
Validation
To evaluate the performance of different methods in predicting
future clinical changes of MCI patients, we perform two sets of
experiments on 88 MCI subjects, including 38 MCI converters
(MCI-C) and 50 MCI non-converters (MCI-NC), from the ADNI
dataset. Each subject has both imaging modalities of data, i.e.,
MRI and PET, at 5 different time points such as baseline (bl), 6-
month (M06), 12-month (M12), 18-month (M18) and 24-month
(M24). Besides MRI and PET imaging data, each subject also has
clinical cognitive scores (i.e., MMSE and ADAS-Cog) at bl, M06,
M12, M18 and M24. In our first set of experiments, we predict the
future MMSE and ADAS-Cog scores at M24 time point by using
all data acquired at the previous time points (including bl, M06,
M12 and M18). Here, besides MRI and PET, we also include
cognitive scores at the previous time points (including bl, M06,
M12 and M18) as additional modality data to further improve the
performance. In our second set of experiments, we predict the
conversion of MCI to AD using both baseline and longitudinal
MRI, PET and cognitive data. Note that those 38 MCI converters
converted at different time points (from M06 to 48 month (M48)),
and thus a flexible number of time points (6-month ahead of the
conversion and up to M18) of data are used for each test subject.
This is different from the regression method where a fixed number
of time points are used for all subjects. It’s worth noting that the
Figure 2. Illustration on longitudinal feature selection.
doi:10.1371/journal.pone.0033182.g002
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longitudinal data in prediction of MCI conversion, so we include
all available longitudinal data (at 6 months ahead of the
conversion). In practice, for a MCI subject, we predict the
conversion by using only the baseline data. However, if the subject
doesn’t convert at later time point, we can then use all data from
baseline to the current time point for refined prediction of
conversion. In this study, a 6-month ahead prediction is
performed, although the same strategy can also be used for
prediction at other amount of time ahead the conversion.
For measuring the regression performance in the first set of
experiments, we use a 10-fold cross-validation strategy by
computing the Pearson’s correlation coefficient (CORR) and the
root mean square error (RMSE) between the predicted and the
actual clinical scores. Specifically, the whole set of subject samples
are equally partitioned into 10 subsets, and each time the subject
samples within one subset are selected as the testing samples and
all other subject samples in the remaining 9 subsets are used for
training the SVM models. This process is repeated for 10 times.
On the other hand, in the second set of experiments, we use a
leave-one-out cross-validation strategy to evaluate the classification
performance, since each subject uses different number of time
points for classification. Classification performance will be
measured by the classification accuracy (i.e., the proportion of
MCI subjects correctly classified), as well as the sensitivity (i.e., the
proportion of MCI converters correctly classified) and the
specificity (i.e., the proportion of MCI non-converters correctly
classified). Besides, we also plot the receiver operating character-
istic (ROC) curve and report the area under the ROC curve
(AUC). In both sets of experiments, SVM is implemented using
LIBSVM toolbox [42], and a linear kernel is used after
normalizing each feature vector with unit norm. For all respective
methods, the values for parameters (e.g.,l and bm) are determined
by performing another round of cross-validation on the training
data. Moreover, in our pre-processing step, we perform feature
normalization, i.e., subtracting the mean and then dividing the
standard deviation (of all training subjects) for each feature value.
Results
Predicting future clinical scores (MMSE and ADAS-Cog)
We first predict the future MMSE and ADAS-Cog scores at
M24 time point by using the data acquired at the previous time
points including baseline (bl), M06, M12 and M18. Before giving
the prediction results, we first plot in Fig. 3 the average
longitudinal changes of MMSE and ADAS-Cog scores at two
sub-groups of MCI patients, i.e., MCI-C and MCI-NC. Table 1
also gives the average MMSE and ADAS-Cog scores at baseline
and 24-month (M24) time points, respectively. It can be seen from
Fig. 3 that, as disease progresses, the cognitive performance of the
MCI-C subjects declines gradually as reflected by the decreased
MMSE and increased ADAS-Cog scores, while the cognitive
performance of the MCI-NC subjects declines much slower than
that of the MCI-C subjects. Furthermore, Table 1 provides the p-
value between baseline and 24-month MMSE (or ADAS-Cog)
scores, indicating that there exist significant difference between
baseline and 24-month for MCI-C group, but no significant
difference for MCI-NC group.
Table 2 shows the performance of the proposed method in
predicting 24-month MMSE and ADAS-Cog scores of MCI
patients, by using different numbers of longitudinal data, from
only the baseline data (bl) to all the available data (bl+M06+
M12+M18). For comparison, we also include the results from the
other two multimodal regression methods, i.e., CONCAT and
Ensemble, which have been used in for predicting future decline in
cognitive scores. Briefly, in the CONCAT method, for each
subject, all data from different modalities and different time points
are first concatenated into a long vector, and then a standard
feature selection method based on Lasso [37] is performed,
followed by using the standard SVM for final regression. On the
other hand, in the Ensemble method, all data from different
modalities and different time points are not concatenated as in the
CONCAT method. Instead, for each modality of each time point,
a standard Lasso feature selection is performed, followed by
classification using an individual SVM, and finally the majority
voting (for classification) or averaging (for regression) is used to fuse
all individual results (from different modalities and time points) at
the decision-making level. It’s worth noting that, in Table 2, for
the CONCAT and Ensemble methods, we report only the results
with use of the baseline data; the results on more numbers of time
points can be found later. Figs. 4–5 further show the scatter plots
of the predicated scores vs. the actual scores of MMSE and ADAS-
Cog by different methods, respectively.
As can be seen from Table 2 and Figs. 4–5, if using only the
baseline data, our proposed (bl) method, which degenerates into a
conventional multi-kernel regression method, achieves only the
slightly better performance than the CONCAT (bl) and Ensemble
(bl) methods on most performance measures. Here, ‘bl’ denotes the
use of only the baseline data in the above methods. On the other
hand, by using the longitudinal data, the performance of our
proposed method can be significantly improved. Specifically, for
predicting MMSE and ADAS-Cog scores at the M24 time point,
our proposed (bl+M06+M12+M18) method achieves the CORR
of 0.786 and 0.777 and the RMSE of 2.035 and 4.004,
respectively, which are much better than the case of using only
the baseline data. Furthermore, to investigate the effect of using
different number of longitudinal data in regression, Table 2 and
Fig. 6 also report the respective results for our proposed method
and other three methods, indicating that the performance of our
proposed method is consistently improved when more and more
longitudinal data are used. Fig. 6 also shows that the use of
longitudinal data can also improve the performance of the
CONCAT and Ensemble methods, but the improvement is much
less than our proposed method. These results show the
effectiveness of using longitudinal data for improved regression,
especially by our proposed method that can effectively use
longitudinal data through longitudinal feature selection and
estimation. Finally, in Fig. 7, we report the result of our proposed
method under different number of time points for two sub-groups
of MCI patients, which again shows the effectiveness of using
longitudinal data for improved performance. Moreover, Fig. 7
shows that it is easier to predict the future changes of MCI-NC
subjects, compared to the MCI-C subjects, since the MCI-NC
subjects have less change in cognitive performance than the MCI-
C subjects as shown in Fig.3.
Predicting future conversion (from MCI to AD)
In this set of experiments, we predict the future conversion of
MCI patients based on both baseline and longitudinal data which
are at least 6-month ahead of the conversion. Table 3 shows the
results of three different methods, i.e., CONCAT, Ensemble, and
our proposed method, in predicting the conversion. Here, for each
method, we include two cases, i.e., one with only baseline data (bl)
and another with both baseline and longitudinal data (bl+lt). As
can be seen from Table 3, the proposed method outperforms the
other two methods on both cases (with or without using
longitudinal data). Specifically, our proposed (bl+lt) method
achieves a classification accuracy of 78.4%, a sensitivity of
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consistently better than the other two methods on each
performance measure. Table 3 also indicates that, by using
longitudinal data, the CONCAT (bl+lt) and Ensemble (bl+lt)
methods can achieve better performance than the CONCAT (bl)
and Ensemble (bl) methods, respectively, but they are still inferior
to our proposed (bl+lt) method.
Moreover, we also investigate the performance of different
methods in predicting conversion of MCI patients under different
conversion time, as shown in Fig. 8. Specifically, Fig. 8(a) gives the
distribution of actual conversion times of the MCI-C subjects, and
Fig. 8(b) gives the classification results for MCI-C subjects under
different conversion time by the three different methods. It’s worth
noting that both baseline and longitudinal data at the time points
such as 6-month and up to M18 ahead of the conversion are used
for each method. Fig. 8 shows that our proposed method
outperforms the other two methods on most cases, especially for
MCI-C subjects who converted at M12 time point, where our
method correctly predicts the conversion for all the 9 subjects with
100% classification accuracy by using both baseline data and
longitudinal data at M06 time point. This again confirms the
efficacy of our proposed method in using longitudinal data for
prediction.
In the above experiments, all methods use multimodality data,
including MRI, PET and cognitive scores. To compare between
multimodality-based method and single-modality based methods,
we generate the three single-modality based methods, namely
MRI-based, PET-based, and Cognitive-based methods, as the
variants of our proposed multimodality-based method. Specifi-
cally, for the MRI-based and PET-based methods, we perform
the corresponding longitudinal feature selection and extraction as
used in our proposed method, but then we perform the standard
SVM based classification, instead of the multi-kernel SVM based
classification. On the other hand, for the Cognitive-based
method, we just concatenate the MMSE and ADAS-Cog scores
from different time points together as features for the subsequent
SVM-based classification. Fig. 9 shows the results of multi-
modality-based and single-modality based methods in predicting
MCI conversion. For the ROC curves shown in Fig. 9(b), we also
compute the corresponding AUC values, obtaining 0.697, 0.676,
0.670 and 0.768 for the MRI-based, PET-based, Cognitive-
based, and our multimodality-based methods, respectively. Our
multimodality-based method achieves much better performance
than the single-modality based methods, which shows the efficacy
of our proposed method in using multimodality data for
prediction.
Figure 3. Average longitudinal changes of clinical scores in MCI patients.
doi:10.1371/journal.pone.0033182.g003
Table 2. Comparison of performance of different methods in predicting 24-month (M24) clinical scores of MCI patients, by using
different numbers of longitudinal data.
Method MMSE ADAS-Cog
CORR RMSE CORR RMSE
CONCAT (bl) 0.63560.049 2.54160.100 0.65760.038 4.77160.146
Ensemble (bl) 0.66660.039 2.63760.081 0.67760.037 4.94360.155
Proposed (bl) 0.65960.043 2.45760.123 0.68260.044 4.76360.084
Proposed (bl+M06) 0.70260.037 2.34460.097 0.74660.028 4.31860.173
Proposed (bl+M06+M12) 0.74360.024 2.17760.113 0.76860.025 4.09760.126
Proposed (bl+M06+M12+M18) 0.78660.013 2.03560.076 0.77760.027 4.00460.086
The reported values are the correlation coefficient (CORR) and the root-mean-square error (RMSE), averaged on 10-fold tests (with standard deviation also reported).
MMSE=Mini-Mental State Examination, ADAS-Cog=Alzheimer’s Disease Assessment Scale - Cognitive Subscale.
doi:10.1371/journal.pone.0033182.t002
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doi:10.1371/journal.pone.0033182.g004
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doi:10.1371/journal.pone.0033182.g006
Figure 7. Regression performance of the proposed method on two sub-groups of MCI patients, when using different number of
longitudinal time points.
doi:10.1371/journal.pone.0033182.g007
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In this subsection, we investigate the top selected brain regions
by our longitudinal feature selection method. It’s worth noting
that for validation of our proposed method in predicting the
future MMSE and ADAS-Cog scores at M24 time point, we use
a 10-fold cross validation with 10 independent runs. For each run
and each fold, an independent longitudinal feature selection is
performed. To determine the top selected brain regions, we count
the frequency of each brain region selected across all folds and all
runs. Figs. 10–11 give the top 20% brain regions detected by our
longitudinal feature selection method on MRI and PET
modalities, respectively. As can be seen from Figs. 10–11, by
jointly considering the longitudinal changes across multiple time
points, our longitudinal feature selection method can select the
relevant brain regions to AD and MCI. For example, Fig. 10
shows that most of the selected top regions, e.g., hippocampal,
amygdale, entorhinal cortex, and parahippocampal regions, are
known to be related to the AD and MCI by many studies using
the group comparison methods [12,43,44,45,46]. On the other
hand, Figs. 10–11 also indicate that there exist different patterns
for MRI and PET images, thus showing the importance of using
both for providing complementary information in prediction.
This also partially explains why the multimodality-based method
can achieve better performance than the single-modality based
methods.
Discussion
In this paper, we have proposed a new regression/classification
method with three major steps, i.e., longitudinal feature selection,
longitudinal feature estimation, and multi-kernel SVM, for
predicting future clinical changes of MCI patients using multi-
modality data from multiple time points. Our proposed method
has been validated on 88 MCI subjects with MRI, PET, and
cognitive scores at 4 different time points including baseline, 6-
month, 12-month and 18-month, through two sets of experiments,
i.e., 1) predicting future MMSE and ADAS-Cog scores at 24-
month time point using both baseline and longitudinal multi-
modality data at previous time points, and 2) predicting future
conversion of MCI subjects using both baseline and longitudinal
multimodality data at least 6-month ahead of the conversion.
Longitudinal feature selection
In this paper, to distinguish from conventional feature selection
methods that are often based on the single (baseline) time point of
data, we call our new feature selection method that works on
multiple (baseline plus longitudinal) time points of data as the
longitudinal feature selection method. The key characteristics of
our longitudinal feature selection method is that the features are
jointly selected from the longitudinal data across multiple time
points, to better reflect the longitudinal change patterns of the
brain with the progression of disease. To the best of our
knowledge, this new type of feature selection problem was not
investigated in the previous studies, and we solved this problem by
formulating it as a linear feature weigh learning with l2,1-norm
regularization, which can be efficiently solved by the existing
multi-task learning methods [38,39,40]. It’s worth noting that, a
few recent works also use the similar multi-task learning techniques
based on l2,1-norm regularization as used in our proposed
longitudinal feature selection method, but they are developed for
different purposes. For example, in [25] and [47], joint regression
and classification is performed via multi-task learning, where the
estimation of each regression or classification variable is regarded
as a different task. However, both methods use only the baseline
data and thus cannot reflect the longitudinal change patterns of
the brain across different time points, which are apparently
different from our longitudinal feature selection method.
Table 3. Comparison of performance of different methods in
predicting the conversion of MCI patients.
Method
Accuracy
(%)
Sensitivity
(%)
Specificity
(%) AUC
CONCAT (bl) 61.4 52.6 68.0 0.691
Ensemble (bl) 58.0 55.3 60.0 0.633
Proposed (bl) 72.7 65.8 78.0 0.745
CONCAT (bl+lt) 70.5 63.2 76.0 0.742
Ensemble (bl+lt) 65.9 57.9 72.0 0.706
Proposed (bl+lt) 78.4 79.0 78.0 0.768
doi:10.1371/journal.pone.0033182.t003
Figure 8. Prediction of conversion of MCI patients under different conversion times.
doi:10.1371/journal.pone.0033182.g008
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A number of high-dimensional regression methods have been
used for predicting future clinical scores (or changes) for MCI
subjects, based on the baseline neuroimaging data. For example,
in [14], a principal component analysis (PCA) based model was
used on the baseline MRI data of 49 MCI subjects (including 20
Figure 9. Classification performance comparison between single-modality vs. multimodality based methods.
doi:10.1371/journal.pone.0033182.g009
Figure 10. Top 20% brain regions detected by the longitudinal feature selection method on MRI images.
doi:10.1371/journal.pone.0033182.g010
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MMSE score, and a correlation coefficient of 0.31 was reported.
In [17], a Bagging relevant vector machine (RVM) was adopted to
predict the future decline of MMSE score from the baseline MRI
data and a correlation coefficient of 0.537 was achieved on 16
MCI-C, 5 MCI-NC, and 5 AD subjects. More recently, in our
previous work, a multi-modal multi-task (M3T) model has been
proposed to predict the 24-month change in MMSE and ADAS-
Cog scores, and the correlation coefficients of 0.511 and 0.531 are
achieved on 38 MCI-C and 42 MCI-NC, as well as 40 AD and 47
HC subjects, respectively. In contrast, by using the longitudinal
data, our proposed method achieves much better correlation
coefficients of 0.786 and 0.777 on 38 MCI-C and 50 MCI-NC
subjects, for predicting 24-month MMSE and ADAS-Cog scores,
respectively. All these results further validate the importance of
using the longitudinal data for improved prediction of future
clinical scores of MCI subjects.
Predicting MCI conversion
A lot of recent studies in early diagnosis of AD has been focused
on predicting the conversion of MCI to AD, i.e., identifying the
MCI converters (MCI-C) from MCI non-converters (MCI-NC)
[10,11,12,15,16]. Specifically, in [12], the accuracy between 75%
and 80% and an maximum AUC of 0.77 were reported on 27
MCI-C and 76 MCI-NC subjects using both baseline and
longitudinal MRI data in the ADNI dataset. In [11], the
maximum accuracy of 61.7% and AUC of 0.734 were reported
on 69 MCI-C and 170 MCI-NC subjects by using both MRI and
CSF data. In [10], the maximum AUC of 0.67 was reported on 86
MCI-C and 128 MCI-NC subjects using the hippocampal atrophy
rates calculated by the boundary shift integral within ROIs. More
recently, in [16], a sensitivity of 63% and specificity of 76% were
reported on 72 MCI-C and 131 MCI-NC subjects by using the
incremental learning method based on spatial frequency repre-
sentation of cortical thickness data, which has been shown better
than the other ten benchmark methods for MCI-C vs. MCI-NC
classification as reported in [15]. In contrast, our method achieves
an accuracy of 78.4%, sensitivity of 79.0%, specificity of 78.0%
and AUC of 0.768, on 38 MCI-C and 50 MCI-NC subjects from
ADNI, which are comparable to the best results reported in
several recent studies on ADNI.
Limitations
The current study is limited by several factors as detailed below.
First, our proposed method performs prediction based on the
longitudinal and multimodality data (i.e., MRI, PET, etc), and
thus requires each subject to have the corresponding modality data
across different time points, which limits the size of subjects that
can be used for study. For example, there are more than 400 MCI
subjects in the ADNI dataset, while there are only 88 MCI subjects
Figure 11. Top 20% brain regions detected by the longitudinal feature selection method on PET images.
doi:10.1371/journal.pone.0033182.g011
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corresponding MMSE and ADAS-Cog scores at multiple time
points (including baseline, 6-month, 12-month and 18-month).
Moreover, besides MRI and PET used in our study, there also
exist other modality data, e.g., CSF and APOE, etc. However,
because our current method requires every subject must have the
same data on all corresponding modalities and the number of
subjects with all modality data (including CSF and APOE) is too
small for reasonable learning, the current study does not consider
data from other modalities (e.g., CSF and APOE).
Conclusion
In summary, our experimental results have demonstrated that
our proposed method which is based on both baseline and
longitudinal multimodality data can effectively predict the future
clinical changes of MCI patients. Specifically, it can effectively
predict the future MMSE and ADAS-Cog scores at 24-month
using both baseline and longitudinal data at previous time points,
and can also predict the conversion of MCI to AD at least 6-
month ahead of the conversion by using both baseline and
longitudinal data. To the best of our knowledge, the longitudinal
feature selection method developed in our method is new in
neuroimaging and deserves further study. In the future work,
besides the group regularization used in our current longitudinal
feature selection, we will also consider adding temporal smooth-
ness constraint between feature weights at adjacent time points, to
further reflect the longitudinal progressive changes of the brain
regions. Moreover, we will develop techniques to deal with
incomplete data in both modalities and time points to overcome
the limitation of small sample size of MCI subjects, for further
improving the final performance. Finally, we want to apply the
technique developed in this paper for diagnosis of other
neuroimaging diseases, e.g., schizophrenia [48,49].
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